Purdue Pharma's 2007 OxyContin criminal settlement and guilty plea

Purdue Pharma's 2007 OxyContin criminal settlement and guilty plea turned years of investigation into a public admission that the company had fraudulently marketed the drug as less prone to abuse and less likely to cause narcotic side effects than immediate-release opioids. Announced in Roanoke, Virginia, the agreement brought substantial financial penalties and misdemeanor pleas from three executives, but no prison terms. Its documentary record exposed how corporate claims about the drug diverged from the company’s own evidence, while its limited penalties left families and local advocates questioning what accountability had actually delivered.

From warning signs to a federal case

The settlement followed years of concern about OxyContin’s risks. The drug’s 1995 application to the U.S. Food and Drug Administration described how crushing a tablet could release its contents immediately rather than in a controlled manner. Clinical trials had recorded withdrawal symptoms, and testing showed that 68 percent of the oxycodone in a crushed pill could be recovered for injection. Those details were available in the application reviewed by Curtis Wright, who approved the drug; Purdue Pharma later claimed it had not known of abuse problems until February 2000. Wright had also cautioned against aggressive competitive promotion, yet minimal restraint was evident in the marketing. He later worked as a consultant for Purdue Pharma.

The case against the company and its executives was once broader than the charges that survived. In 2006, federal prosecutors considered felony charges including mail fraud, wire fraud, and money laundering, in addition to misbranding. Negotiations narrowed the case as Purdue Pharma’s lawyers lobbied against felony charges for executives and argued over the amount to be paid. Purdue Pharma initially offered $10 million, while the government’s initial proposal was $1 billion. In October, on the night before the plea agreement was due to expire, a senior Justice Department officer called prosecutor John Brownlee at home, at the request of a Purdue Pharma lawyer, to urge more time. Brownlee did not extend the deadline. Purdue Pharma accepted the agreement that night rather than risk more serious charges or a jury trial in western Virginia.

The evidence made public

On a clear day in May 2007, Brownlee announced the settlement in the atrium of a downtown Roanoke office building. Behind him stood the prosecutors, including Gregg Wood, Randy Ramseyer, and Rick Mountcastle; beside them, columns of cardboard containers filled with documents, depositions, and data from the investigation. The team had collected records in about two thousand containers, so many that Brownlee had rented additional storage space in an Abingdon strip mall. The scale of the archive gave the announcement a physical measure: the case rested not on a single disputed claim but on accumulated records.

Brownlee displayed Purdue Pharma’s promotional charts beside clinical data drawn from the company’s own studies. The company’s charts presented OxyContin as producing smooth, sustained blood levels, with fewer peaks and valleys; the actual data showed steep fluctuations. The contrast illustrated how marketing material had made the drug appear to behave more evenly than the underlying evidence supported. The charts represented two of 46 assertions in a statement of facts that Purdue Pharma agreed to as part of the plea.

Other agreed facts described the handling of evidence that reflected poorly on the drug. Early reports of patients experiencing withdrawal were not written up after a supervisor warned that doing so might worsen negative publicity. Some sales representatives claimed that oxycodone was harder to extract from OxyContin for intravenous use than other pain medicines, although the company’s own study found that 68 percent could be recovered from one pill. Purdue Pharma also conceded that some representatives falsely described OxyContin as less euphoric and less likely to be diverted than drugs such as Percocet, and as a way to identify or exclude people seeking drugs. These were not merely disputes about the meaning of a promotional slogan: the settlement established that the company had knowingly made false claims and suppressed information relevant to abuse and withdrawal.

Pleas, families, and the sentencing hearing

Under the agreement, Purdue Pharma pleaded guilty to felony misbranding for six years of fraudulent marketing. It would pay $600 million to resolve federal criminal and civil misbranding charges. Paul Goldenheim, Michael Friedman, and Howard Udell pleaded guilty to misdemeanor versions of the offense, with $34.5 million paid on their behalf by the company. Together, the fines totaled $634.5 million. The penalty against Purdue Pharma amounted to about 90 percent of its profits from OxyContin’s 1996 launch through 2001, when the company removed language suggesting the drug’s timed-release mechanism reduced abuse liability. It was then the eleventh-largest fine paid by a pharmaceutical company in Justice Department history.

The agreement also set up a July sentencing hearing in Abingdon, where parents who had lost family members to OxyContin were invited to address the court. On July 20, 2007, families arrived in steady rain to see the three executives in the federal courthouse and to speak publicly about the drug’s effects. Many opposed the agreement’s provision that the executives would serve no jail time and asked James P. Jones to reconsider incarceration. Their testimony made a financial settlement answerable, at least in the courtroom, to the people whose losses had otherwise remained outside the language of corporate penalties.

Ramseyer emphasized that the executives, by accepting the pleas, acknowledged that they had not been powerless to prevent the misbranding and had a duty to ensure it did not occur. He also warned that the company’s public-relations response would seek to minimize the crimes. The defense, in turn, pointed to measures Purdue Pharma had taken against diversion and fraud, and maintained that Friedman had not personally participated in misconduct. The opposing accounts underscored the settlement’s tension: the pleas established corporate and executive responsibility, while the agreement stopped short of prison sentences or a trial that might have tested a wider set of charges.

Penalties and their limits

Goldenheim, Friedman, and Udell received three years of probation and were ordered to complete 400 hours of community service in drug-abuse or drug-treatment programs. The agreement did not require prison, despite the families’ appeals. Art Van Zee and Sister Beth Davies regarded the settlement with both satisfaction and regret: they welcomed consequences for Purdue Pharma and its executives, but were angry that the fine would not directly fund treatment in the medically underserved region most affected by the drug. The Lee County sheriff’s office received only placebo OxyContin tablets for use in drug stings.

The money was divided among law enforcement, state and federal Medicaid programs, and the creation of Virginia’s prescription-monitoring program; $130 million went toward settling civil claims. The corporate distinction also mattered. Purdue Frederick, Purdue Pharma’s holding company, was barred for five years from participating in Medicaid, Medicare, and Tricare, while Purdue Pharma itself remained eligible to participate in those programs and could continue selling OxyContin. The executives were separately barred from doing business with federal health programs and repeatedly appealed that decision, without success.

The settlement therefore carried two meanings at once. It made a large body of internal evidence public and secured guilty pleas acknowledging fraudulent marketing; it also left the most visible punishment financial, denied the executives prison terms, and directed no part of the fine to the locally needed treatment Van Zee and Davies sought. Its courtroom statements and documentary displays gave families a formal record of wrongdoing, but the distribution of penalties showed how limited that recognition could be when measured against the consequences they described.